Table 1.
Baseline clinico‐pathological characteristics of patients with lung cancer
| All (n = 1772) | |
|---|---|
| Age, mean ± SD | 60.78 ± 9.46 |
| Sex, n (%) | |
| Men | 1134 (64.0) |
| Women | 638 (36.0) |
| BMI, mean ± SD | 22.89 ± 3.40 |
| Pathological type, n (%) | |
| NSCLC | 791 (44.6) |
| SCLC | 233 (13.1) |
| Other | 748 (42.2) |
| Smoke, n (%) | |
| No | 696 (39.3) |
| Yes | 1076 (60.7) |
| Alcohol, n (%) | |
| No | 1314 (74.2) |
| Yes | 458 (25.8) |
| Co‐morbidities, n (%) | |
| No | 1062 (59.9) |
| Yes | 710 (40.1) |
| Tumour history, n (%) | |
| No | 1456 (82.2) |
| Yes | 316 (17.8) |
| TNM stage, n (%) | |
| I | 129 (7.3) |
| II | 264 (14.9) |
| III | 462 (26.1) |
| IV | 917 (51.7) |
| Surgery, n (%) | |
| No | 1369 (77.3) |
| Yes | 403 (22.7) |
| Radiotherapy, n (%) | |
| No | 1582 (89.3) |
| Yes | 190 (10.7) |
| Chemotherapy, n (%) | |
| No | 525 (29.6) |
| Yes | 1247 (70.4) |
| KPS, mean ± SD | 85.91 ± 11.75 |
| <70 | 93 (5.2) |
| ≥70 | 1679 (94.8) |
| PG‐SGA, mean ± SD | 5.27 ± 4.43 |
| Total protein, median (IQR) | 68.95 (64.93–73) |
| Albumin, median (IQR) | 39.3 (36.28–42.1) |
| C‐reaction protein, median (IQR) | 5.595 (3.02–20.925) |
| Glucose, median (IQR) | 5.39 (4.91–6.0925) |
| Haemoglobin, median (IQR) | 131.0 (117.0–142.0) |
| Neutrophil, median (IQR) | 4.165 (2.97–5.74) |
| Lymphocyte, median (IQR) | 1.57 (1.18–2.01) |
| Red blood cell, median (IQR) | 4.35 (3.94–4.72) |
| Platelets, median (IQR) | 238 (187–296) |
| NLR, median (IQR) | 2.61 (1.78–4.12) |
| PLR, median (IQR) | 151.42 (108.62–211.65) |
| GLR, median (IQR) | 3.50 (2.64–4.94) |
| ALI, median (IQR) | 34.84 (20.31–53.62) |
| SII, median (IQR) | 617.94 (365.14–1040.58) |
| CAR, median (IQR) | 0.14 (0.07–0.55) |
| CONUT, n (%) | |
| <2 | 852 (48.1) |
| ≥2 | 920 (51.9) |
| mGPS, n (%) | |
| 0 | 1099 (62.0) |
| 1 | 453 (25.6) |
| 2 | 220 (12.4) |
| GNRI, median (IQR) | 98.88 (93.22–103.20) |
| mGNRI, median (IQR) | 43.25 (41.61–46.46) |
| AGR, median (IQR) | 1.34 (1.15–1.54) |
| PNI, median (IQR) | 47.4 (43.5–51.4) |
| NRI, median (IQR) | 100.06 (94.26–104.50) |
| LCS, n (%) | |
| 0 | 358 (20.2) |
| 1 | 1209 (68.2) |
| 2 | 205 (11.6) |
| LCR, median (IQR) | 2694.61 (676.41–6432.80) |
AGR, albumin‐to‐globulin ratio; ALI, advanced lung cancer inflammation index; BMI, body mass index; CAR, C‐reactive protein‐to‐albumin ratio; CONUT score, controlling nutritional status score; GLR, glucose‐to‐lymphocyte ratio; GNRI, geriatric nutritional risk index; KPS, Karnofsky performance scoring; LCR, lymphocyte‐to‐C‐reactive protein ratio; mGNRI, modified geriatric nutritional risk index; mGPS, modified Glasgow prognostic score; NLR, neutrophil‐to‐lymphocyte ratio; NRI, nutritional risk index; LCS, lymphocyte‐to‐C‐reactive protein ratio score; NSCLC, non‐small cell lung cancer; PG‐SGA, Patient‐Generated Subjective Global Assessment; PLR, platelet‐to‐lymphocyte ratio; PNI, prognostic nutritional index; SCLC, small cell lung cancer; SD, standard deviation; SII, systemic immune‐inflammation index.